Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Biosciences, Transgenomic

Premium

Amersham Biosciences has launched its CodeLink Human P450 SNP Bioarray. The company expects drug makers to use the chip when screening clinical trial populations for individuals’ toxicogenomic profile.

Amersham also said the chip may be used to determine new phenotypes linked to P450 mutation. The chip genotypes 110 SNPs within nine P450 drug metabolism genes — CYP1A1, 1A2, 1B1, 2C9, 2C19, 2D6, 2E, 3A4, and 3A5.

The release comes around three months after Roche launched its own cytochrome P450 product, called Amplichip. This product is the subject of a letter issued by the US Food and Drug Administration in July questioning why Roche had marketed the Amplichip as an analyte-specific reagent.


Transgenomic has launched the Surveyor line of consumables for use in SNP detection. The key component of the mutation-detection kit is an enzyme that “cleaves DNA at points where any type of DNA sequence variation exists,” which Transgenomic calls “a significant improvement” over existing enzymes in its class.

The company said the genetic fragments can then be analyzed by fluorescent capillary electrophoresis, standard gel electrophoresis, or by Transgenomic’s Wave platform.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.